DEVELOPMENT pipeline
Reinvesting our profit to discover new medicines
At Servier, we choose to reinvest our profit to discover new medicines. Our development pipeline offers a tangible reflection of this commitment. Over recent years, it has expanded to comprise 75 projects, 43 of which in development and 32 research projects.
This innovative pipeline currently offers considerable potential for the Group to differentiate itself and create value, with 50% of projects deemed to be first in class.
Oncology
SOLID TUMORS
FTD/TPI combo bevacizumab
S95005
Solid tumors (new indication)
Territory
Worldwide ex-US/CAN, MEX & Asia
Futuximab / modotuximab
combo FTD/TPI
S95026
Solid tumors (new indication)
Territory
Worldwide ex-US/CAN, MEX & Asia
Vorasidenib
S95032
Low grade Glioma with IDH 1/2 mutation
Ivosidenib
S95031
Solid tumors (new indication)
Anti-MET
S95027
Non small Cell Lung Cancer
Vorasidenib + pembrolizumab
S95032
Grade 2-3 glioma with IDH1/2 mutation
Ivosidenib combo
S95031
Solid tumors (new indication)
Anti-TIM3 combo
S95018
Solid tumors
Anti-CD73
S95024
Solid tumors
Anti-PD-L1/4-1BB
S95012
Solid tumors
Territory
Worldwide ex-US
Anti-NKG2A
S95029
Solid tumors
Inhibiteur de MAT2A
S95035
Solid tumors
Anti-FLT3
S95040
Solid tumors
HEMATOLOGICAL MALIGNANCIES
Ivosidenib + 7+3 (chimio)
S95031
Hematological malignancies (new indication)
UCART 19
S68587/S95023
Hematological malignancies
Territory
Worldwide ex-US
Calaspargase pegol
S95015
Hematological malignancies (new indication)
Pegaspargase
S95014
Hematological malignancies (new formulation)
Ivosidenib
S95031
Hematological malignancies (new indication)
BCL-2 inhibitor + Mcl1 inhibitor (S64315)
S65487
Acute Myeloid Leukemia
Territory
Worldwide ex-US/CAN, JAP, some EU countries
BCL-2 inhibitor + azacitidine
S65487
1st line Acute Myeloid Leukemia (AML)
Territory
Worldwide ex-US/CAN, JAP, some EU countries
Mcl1 inhibitor + azacitidine
S64315
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Territory
Worldwide ex-US/CAN, JAP, some EU countries
Neuroscience
LRRK2 inhibitor
S221237
Parkinson’s Disease
Immuno-inflammation
Anti-IL7R
S95011
Sjögren syndrome
Anti-IL7R
S95011
Ulcerative colitis
PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3; FTD/TPI: trifluridine/ tipiracil; EGFR: epidermal growth factor receptor; IDH: Isocitrate dehydrogenase; AYA: Adolescents and Young Adults; MOA: Mode of Action